KEYTRUDA ® (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress
Dateline City:
KENILWORTH, N.J. Results from KEYNOTE-010 Include Improved Patient-Reported Health-Related Quality of Life Outcomes and 18-Month Findings of Overall Survival and Progression-Free Survival in Previously Treated Patients Whose Tumors Express PD-L1 (Tumor Proportion Score of One Percent or More)
KENILWORTH, N.J.--(BUSINESS WIRE)--
Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that KEYTRUDA® (pembrolizumab), the company ’s
anti-PD-1 therapy, demonstrated superiority in overall survival (OS) at
18 months compared to standard of care chemotherapy (docetaxel) in
patients with metastatic non-small cell lung cancer (NSCLC) previously
treated with platinum-containing chemotherapy whose tumor s expressed
PD-L1 (tumor proportion score [TPS] of one percent or more), as well as
patients with high levelsLanguage:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer ESMO Keytruda MSD NYSE:MRK Source Type: news
More News: Drugs & Pharmacology